Edison Investment Research - Capstone Therapeutics (CAPS) QuickView: A new class of cardiovascular drug

Report

Edison Investment Research

QuickView: A new class of cardiovascular drug

First clinical data for AEM-28, an Apo-E mimetic, is expected during H214, which could pave the way for continued development in an orphan cardiovascular (CV) indication, although additional funds will likely be needed if data are positive. Preclinical data suggest AEM-28 can lower cholesterol and protect the artery wall; this profile could have utility in broader CV indications, although development is still at an early stage.

15/07/2014 2 EN

Underlying

Capstone Therapeutics

See profile

United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

QuickView: Focus on acute pancreatitis

Capstone is investigating a promising new indication for its Apo-E mimetics triglyceride lowering in acute pancreatitis, an orphan indication with high unmet medical need and requiring only small, rapid clinical trials. AEM-28 has demonstrated significant reductions in VLDL and triglycerides in its Phase I/IIa programme and development for follow-on AEM-28-02 is underway. However, new funding will be needed to progress clinical trials.

April 27, 2015 April 27, 2015 2 EN

Edison Investment Research

QuickView: Initial proof-of-concept established

AEM-28 has demonstrated significant reductions in both VLDL and triglycerides in the Phase I/II programme. This reinforces prior lipid biomarker trends observed in healthy volunteers. These data provide initial proof-of-concept for AEM-28, and more broadly for follow-on products within Capstoneâ€™s Apo-E mimetic pipeline including AEM-28-02, supporting progression into further trials, although additional funding will be needed. Future development could include an orphan indication, requiring only small trials for approval, in addition to potential in major CV disorders.

December 17, 2014 December 17, 2014 2 EN

Edison Investment Research

QuickView: First human lipid biomarker trends

Early data in healthy volunteers have demonstrated trends in favour of AEM-28 on a number of lipid biomarkers, even at low doses. These are the first-in-man data, which hint at potential future efficacy. AEM-28 continues to be investigated in a Phase Ib/IIa trial, with data anticipated by YE14/Q115. These could pave the way for future development in an orphan cardiovascular indication, although additional funds will likely be needed if data are positive.

September 15, 2014 September 15, 2014 2 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: A new class of cardiovascular drug

QuickView: Focus on acute pancreatitis

QuickView: Initial proof-of-concept established

QuickView: First human lipid biomarker trends

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe